Tenascin-C in primary Merkel cell carcinoma.
OBJECTIVE
Merkel cell carcinoma (MCC) is a rare malignant cutaneous neuroendocrine tumour that mostly affects the elderly. It shows rapid progression of the primary tumour, together with a vertical growth pattern into the underlying subcutaneous tissue. Metastatic dissemination to regional lymph nodes is early and frequent. Tenascin-C (Tn-C) is a large extracellular matrix glycoprotein that is expressed in various benign and malignant processes. Expression of Tn-C is also associated with invasion and cellular proliferation, and is often downregulated in fully evolved advanced carcinomas. In previous studies, Tn-C expression correlated with prognosis in tumours of different origin.


METHODS
Immunohistochemistry was used to investigate the expression of Tn-C in 25 MCC specimens and to evaluate the prognostic importance of this glycoprotein.


RESULTS
Seventeen samples expressed Tn-C. Staining was mainly seen in the invasion borders and within the connective tissue septae inside the tumours. The expression of Tn-C correlated significantly with large tumour size. There was also frequent expression of Tn-C in primary tumours with metastatic dissemination. Most of the Tn-C negative samples were of small size.


CONCLUSIONS
Tn-C expression seems to increase with tumour size and malignant behaviour. Expression was slightly enhanced in tumours with high proliferative indices. Expression is seen mainly in areas of invasive growth and, in this respect, resembles that of other invasive tumours.
Koljonen
V
V
Department of Plastic Surgery, Helsinki University Hospital, Helsinki, 00029 HUS, Finland. virve.koljonen@hus.fi
Jahkola
T
T
Tukiainen
E
E
Granroth
G
G
Haglund
C
C
Böhling
T
T
D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015266:Carcinoma, Merkel Cell / Q000378:metabolism* / Q000473:pathology / Q000556:secondary; D002455:Cell Division; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000378:metabolism*; D011379:Prognosis; D012878:Skin Neoplasms / Q000378:metabolism* / Q000473:pathology; D019063:Tenascin / Q000378:metabolism*
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D019063:Tenascin
Hum Pathol. 2000 Jan;31(1):58-62
10665914
Nat Med. 1999 Jun;5(6):662-8
10371505
Int J Cancer. 2002 Mar 20;98(3):362-9
11920587
Forensic Sci Int. 2002 Apr 18;126(2):118-22
12084487
Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3
12182416
Oncology. 2003;64(3):245-50
12697965
Anticancer Res. 2003 May-Jun;23(3C):3051-6
12926160
Eur J Surg Oncol. 2003 Sep;29(7):607-10
12943628
Int J Cancer. 2004 Jan 1;108(1):31-40
14618612
APMIS. 2004 Jan;112(1):39-44
14961973
Anticancer Res. 2003 Nov-Dec;23(6C):4587-91
14981900
Cancer Res. 1983 Jun;43(6):2796-805
6342760
Sci Am. 1986 Jun;254(6):42-51
3010451
Dev Biol. 1988 Aug;128(2):245-55
2456233
Annu Rev Cell Biol. 1989;5:71-92
2480799
J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):254-6
2170468
Br J Dermatol. 1991 Jan;124(1):13-20
1704250
Int J Cancer. 1991 Apr 1;47(6):811-6
1707033
Am J Pathol. 1991 Nov;139(5):1143-50
1719820
Invasion Metastasis. 1991;11(6):325-31
1726610
Development. 1993 Apr;117(4):1183-98
8404525
Perspect Dev Neurobiol. 1994;2(1):111-16
7530137
Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):315-23
7836085
Methods Enzymol. 1994;245:52-61
7539094
Int Arch Allergy Immunol. 1995 Aug;107(4):484-90
7620364
Int J Cancer. 1996 Dec 20;69(6):445-7
8980244
Matrix Biol. 1998 Aug;17(4):305-16
9749946
Clin Cancer Res. 1995 Sep;1(9):1035-41
9816077
Br J Cancer. 1998 Dec;78(11):1507-13
9836485
Eur J Cancer. 1998 Oct;34(11):1687-92
9893653
Am J Dermatopathol. 1999 Feb;21(1):16-20
10027519
Gynecol Oncol. 1999 Jun;73(3):415-21
10366470
Surg Neurol. 2000 Sep;54(3):235-40
11118570